Literature DB >> 29463509

Ventricular Fibrillation Conversion Testing After Implantation of a Subcutaneous Implantable Cardioverter Defibrillator: Report From the National Cardiovascular Data Registry.

Daniel J Friedman1,2, Craig S Parzynski3, E Kevin Heist4, Andrea M Russo5, Joseph G Akar3, James V Freeman3, Jeptha P Curtis3, Sana M Al-Khatib6,2.   

Abstract

BACKGROUND: Compared with transvenous implantable cardioverter defibrillators (ICDs), subcutaneous (S)-ICDs require a higher energy for effective defibrillation. Although ventricular fibrillation conversion testing (CT) is recommended after S-ICD implantation to ensure an adequate margin between the defibrillation threshold and maximum device output (80J), prior work found that adherence to this recommendation is declining.
METHODS: We studied first-time recipients of S-ICDs (between September 28, 2012, and April 1, 2016) in the National Cardiovascular Database Registry ICD Registry to determine predictors of use of CT, predictors of an insufficient safety margin (ISM, defined as ventricular fibrillation conversion energy >65J) during testing, and inhospital outcomes associated with use of CT. Multivariable logistic regression analysis was used to predict use of CT and ISM. Inverse probability weighted logistic regression analysis was used to examine the association between use of CT and inhospital adverse events including death.
RESULTS: CT testing was performed in 70.7% (n=5624) of 7960 patients with S-ICDs. Although deferral of CT was associated with several patient characteristics (including increased body mass index, increased body surface area, severely reduced ejection fraction, dialysis dependence, warfarin use, anemia, and hypertrophic cardiomyopathy), the facility effect was comparatively more important (area under the curve for patient level versus generalized linear mixed model: 0.619 versus 0.877). An ISM occurred in 6.9% (n=336) of 4864 patients without a prior ICD and was more common among white patients and those with ventricular pacing on the preimplant ECG, higher preimplant blood pressure, larger body surface area, higher body mass index, and lower ejection fraction. A risk score was able to identify patients at low (<5%), medium (5% to 10%), and high risk (>10%) for ISM. CT testing was not associated with a composite of inhospital complications including death.
CONCLUSIONS: Use of CT testing after S-ICD implantation was driven by facility preference to a greater extent than patient factors and was not associated with a composite of inhospital complications or death. ISM was relatively uncommon and is associated with several widely available patient characteristics. These data may inform ICD system selection and a targeted approach to CT.
© 2018 American Heart Association, Inc.

Entities:  

Keywords:  defibrillation; implantable cardioverter defibrillator; subcutaneous implantable cardioverter defibrillator

Mesh:

Year:  2018        PMID: 29463509      PMCID: PMC5988932          DOI: 10.1161/CIRCULATIONAHA.117.032167

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  21 in total

1.  Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: a matched analysis using propensity scores.

Authors:  S T Normand; M B Landrum; E Guadagnoli; J Z Ayanian; T J Ryan; P D Cleary; B J McNeil
Journal:  J Clin Epidemiol       Date:  2001-04       Impact factor: 6.437

2.  2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing.

Authors:  Bruce L Wilkoff; Laurent Fauchier; Martin K Stiles; Carlos A Morillo; Sana M Al-Khatib; Jesús Almendral; Luis Aguinaga; Ronald D Berger; Alejandro Cuesta; James P Daubert; Sergio Dubner; Kenneth A Ellenbogen; N A Mark Estes; Guilherme Fenelon; Fermin C Garcia; Maurizio Gasparini; David E Haines; Jeff S Healey; Jodie L Hurtwitz; Roberto Keegan; Christof Kolb; Karl-Heinz Kuck; Germanas Marinskis; Martino Martinelli; Mark McGuire; Luis G Molina; Ken Okumura; Alessandro Proclemer; Andrea M Russo; Jagmeet P Singh; Charles D Swerdlow; Wee Siong Teo; William Uribe; Sami Viskin; Chun-Chieh Wang; Shu Zhang
Journal:  Heart Rhythm       Date:  2015-12-01       Impact factor: 6.343

3.  Risk Factors for Inadequate Defibrillation Safety Margins Vary With the Underlying Cardiac Disease: Implications for Selective Testing Strategies.

Authors:  Judith L Bonnes; Sjoerd W Westra; Leon H R Bouwels; Menko Jan DE Boer; Marc A Brouwer; Joep L R M Smeets
Journal:  J Cardiovasc Electrophysiol       Date:  2016-03-09

4.  Multiple imputation of discrete and continuous data by fully conditional specification.

Authors:  Stef van Buuren
Journal:  Stat Methods Med Res       Date:  2007-06       Impact factor: 3.021

5.  Subcutaneous implantable cardioverter-defibrillator Post-Approval Study: Clinical characteristics and perioperative results.

Authors:  Michael R Gold; Johan D Aasbo; Mikhael F El-Chami; Mark Niebauer; John Herre; Jordan M Prutkin; Bradley P Knight; Steven Kutalek; Kevin Hsu; Raul Weiss; Eric Bass; Michael Husby; Timothy M Stivland; Martin C Burke
Journal:  Heart Rhythm       Date:  2017-05-11       Impact factor: 6.343

6.  Trends and In-Hospital Outcomes Associated With Adoption of the Subcutaneous Implantable Cardioverter Defibrillator in the United States.

Authors:  Daniel J Friedman; Craig S Parzynski; Paul D Varosy; Jordan M Prutkin; Kristen K Patton; Ali Mithani; Andrea M Russo; Jeptha P Curtis; Sana M Al-Khatib
Journal:  JAMA Cardiol       Date:  2016-11-01       Impact factor: 14.676

7.  A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group.

Authors:  A S Levey; J P Bosch; J B Lewis; T Greene; N Rogers; D Roth
Journal:  Ann Intern Med       Date:  1999-03-16       Impact factor: 25.391

8.  Implant and Midterm Outcomes of the Subcutaneous Implantable Cardioverter-Defibrillator Registry: The EFFORTLESS Study.

Authors:  Lucas Boersma; Craig Barr; Reinoud Knops; Dominic Theuns; Lars Eckardt; Petr Neuzil; Marcoen Scholten; Margaret Hood; Juergen Kuschyk; Paul Jones; Elizabeth Duffy; Michael Husby; Kenneth Stein; Pier D Lambiase
Journal:  J Am Coll Cardiol       Date:  2017-08-15       Impact factor: 24.094

9.  Cardioverter defibrillator implantation without induction of ventricular fibrillation: a single-blind, non-inferiority, randomised controlled trial (SIMPLE).

Authors:  Jeff S Healey; Stefan H Hohnloser; Michael Glikson; Jorg Neuzner; Phillipe Mabo; Xavier Vinolas; Josef Kautzner; Gilles O'Hara; Lieselot VanErven; Fredrik Gadler; Janice Pogue; Ursula Appl; Jim Gilkerson; Thierry Pochet; Kenneth M Stein; Bela Merkely; Susan Chrolavicius; Brandi Meeks; Csaba Foldesi; Bernard Thibault; Stuart J Connolly
Journal:  Lancet       Date:  2015-02-23       Impact factor: 79.321

10.  Patient, physician, and procedural factors influencing the use of defibrillation testing during initial implantable cardioverter defibrillator insertion: findings from the NCDR®.

Authors:  Andrea M Russo; Yongfei Wang; Sana M Al-Khatib; Jeptha P Curtis; Rachel Lampert
Journal:  Pacing Clin Electrophysiol       Date:  2013-08-26       Impact factor: 1.976

View more
  8 in total

1.  Response by Friedman and Al-Khatib to Letter Regarding Article, "Ventricular Fibrillation Conversion Testing After Implantation of a Subcutaneous Implantable Cardioverter Defibrillator: Report From the National Cardiovascular Data Registry".

Authors:  Daniel J Friedman; Sana M Al-Khatib
Journal:  Circulation       Date:  2018-12-18       Impact factor: 29.690

2.  Complications involving the subcutaneous implantable cardioverter-defibrillator: Lessons learned from MAUDE.

Authors:  Emily P Zeitler; Daniel J Friedman; Zak Loring; Kristen B Campbell; Sarah A Goldstein; Zachary K Wegermann; Jane Schutz; Nicole Smith; Eric Black-Maier; Sana M Al-Khatib; Jonathan P Piccini
Journal:  Heart Rhythm       Date:  2019-09-24       Impact factor: 6.343

Review 3.  Subcutaneous and Transvenous ICDs: an Update on Contemporary Questions and Controversies.

Authors:  Daniel J Friedman; Albert S Tully; Emily P Zeitler
Journal:  Curr Cardiol Rep       Date:  2022-05-31       Impact factor: 3.955

4.  Trends in Use and In-Hospital Outcomes of Subcutaneous Implantable Cardioverter Defibrillators in Patients Undergoing Long-Term Dialysis.

Authors:  Patrick H Pun; Craig S Parzynski; Daniel J Friedman; Gillian Sanders; Jeptha P Curtis; Sana M Al-Khatib
Journal:  Clin J Am Soc Nephrol       Date:  2020-09-23       Impact factor: 8.237

5.  The impact of transvenous cardioverter-defibrillator implantation on quality of life, depression and optimism in dialysis patients: report on the secondary outcome of QOL in the randomized controlled ICD2 trial.

Authors:  Rohit J Timal; Veronique de Gucht; Joris I Rotmans; Liselotte C R Hensen; Maurits S Buiten; Mihaly K de Bie; Hein Putter; Martin J Schalij; Ton J Rabelink; J Wouter Jukema
Journal:  Qual Life Res       Date:  2021-02-19       Impact factor: 4.147

6.  Subcutaneous implantable cardioverter-defibrillators: long-term results of the EFFORTLESS study.

Authors:  Pier D Lambiase; Dominic A Theuns; Francis Murgatroyd; Craig Barr; Lars Eckardt; Petr Neuzil; Marcoen Scholten; Margaret Hood; Jȕrgen Kuschyk; Amy J Brisben; Nathan Carter; Timothy M Stivland; Reinoud Knops; Lucas V A Boersma
Journal:  Eur Heart J       Date:  2022-06-01       Impact factor: 35.855

7.  Successful defibrillation verification in subcutaneous implantable cardioverter-defibrillator recipients by low-energy shocks.

Authors:  Mauro Biffi; Matteo Ziacchi; Andrea Angeletti; Andrea Castelli; Giulia Massaro; Cristian Martignani; Mariolina Lovecchio; Sergio Valsecchi; Igor Diemberger
Journal:  Clin Cardiol       Date:  2019-04-25       Impact factor: 2.882

8.  Approaches to Minimizing Periprocedural Complications During Subcutaneous Implantable Cardioverter-defibrillator Placement.

Authors:  Srikanth Vedachalam; Schuyler Cook; Tanner Koppert; Toshimasa Okabe; Raul Weiss; Muhammad R Afzal
Journal:  J Innov Card Rhythm Manag       Date:  2020-05-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.